<DOC>
	<DOCNO>NCT00396201</DOCNO>
	<brief_summary>Participants Hodgkin 's Disease ( HD ) treat cyto-reductive chemotherapy , undergo autologous stem cell transplantation , meet inclusion/exclusion criterion eligible enter efficacy , safety pharmacokinetic ( PK ) study . The change standard care addition plerixafor granulocyte-colony stimulating factor ( G-CSF ) mobilization regimen day prior apheresis . The purpose protocol determine proportion participant reach target number CD34+ stem cell ( ≥5*10^6 cells/kg ) hematopoietic stem cell mobilization G-CSF plerixafor . Safety PK parameter also collect .</brief_summary>
	<brief_title>AMD3100 ( Plerixafor ) Added Mobilizing Regimen Granulocyte-colony Stimulating Factor ( G-CSF ) Increase Number Peripheral Blood Stem Cells ( PBSCs ) Patients With Hodgkin 's Disease</brief_title>
	<detailed_description>Participants HD treat cyto-reductive chemotherapy , undergo autologous stem cell transplantation , meet inclusion/exclusion criterion eligible enter study . The change standard care addition plerixafor G-CSF mobilization regimen day prior apheresis collection blood sample pharmacokinetic ( PK ) analysis pharmacodynamics ( PD ) analysis CD34+ fluorescence-activated cell sort ( FACS ) analysis . Blood sample PK CD34+ FACS analysis obtain prior first dose plerixafor . Participants undergo mobilization G-CSF ( 10 µg/kg daily ) receive plerixafor ( 240 µg/kg ) day prior apheresis . Participants apheresed 5 consecutive day order collect target number CD34+ stem cell , ( ≥5*10^6 cells/kg ) . After apheresis , participant treat high dose chemotherapy preparation transplantation . Participants transplant cell obtain G-CSF plus plerixafor mobilization regimen . In event sufficient number cell transplantation obtain collection , cell may retain pooled transplantation investigator 's discretion . The primary endpoint proportion HD participant collect ≥5*10^6 CD34+ cells/kg mobilization regimen . The secondary endpoint include safety mobilization regimen , proportion participant collect ≥2*10^6 CD34+ cells/kg , change CD34+ cell circulate peripheral blood dose plerixafor , number day apheresis require obtain ≥5*10^6 CD34+ cells/kg . In addition , success transplantation evaluate measuring time engraftment PMNs PLTs . Participants follow 12 month assess transplant durability . This study previously post AnorMED , Inc . In November 2006 , AnorMED , Inc. acquire Genzyme Corporation . Genzyme Corporation sponsor trial .</detailed_description>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Diagnosis HD eligible autologous transplantation No 3 prior regimen chemotherapy ( Rituximab consider chemotherapy purpose study . ) 4 week since last cycle chemotherapy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 The patient recover acute toxic effect prior chemotherapy White blood cell count ( WBC ) &gt; 3.0*10^9/L Absolute polymorphonuclear cell ( PMN ) count &gt; 1.5*10^9/L Platelet ( PLT ) count &gt; 100*10^9/L Serum creatinine ≤2.2 mg/DL Serum glutamic oxaloacetic transaminase ( SGOT ) , serum glutamic pyruvic transaminase ( SGPT ) total bilirubin &lt; 2 x upper limit normal ( ULN ) Left ventricle ejection fraction &gt; 45 % normal echocardiogram multiplegated acquisition ( MUGA ) scan Forced expiratory volume lung first second ( FEV1 ) &gt; 60 % predict diffusing capacity lung carbon monoxide ( DLCO ) &gt; 45 % predict Negative human immunodeficiency virus ( HIV ) A comorbid condition , view investigator , render patient high risk treatment complication Patients fail previous collection A residual acute medical condition result prior chemotherapy Hodgkin 's disease involve central nervous system Acute infection Fever ( temp &gt; 38°C/100.4°F ) Patients whose actual body weight exceeds 150 % ideal body weight History ventricular arrhythmia History paresthesia Patients previously receive experimental therapy within 4 week enrol study currently enrol another experimental study mobilization period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Hodgkin 's Disease</keyword>
	<keyword>Stem cell mobilization</keyword>
	<keyword>apheresis</keyword>
</DOC>